Raygent.com Business Development And Intelligence For Healthcare Markets

Home
Buzzwords
About Us
- Subscribe
Articles
Archives
- Timeline
Contact Us

Find Us Online:

BIOgraph
Biopharmaceuticals Portfolio
- 2013 Rayno Biopharmaceuticals Portfolio
Diagnostics and Tools Portfolio
- 2013 Rayno Tools and Diagnostics Portfolio
Life Science ETF's and Mutual Funds
- 2009-2012 Life Science Portfolios
Other
- Company Profiles
- Energy
- Macro
- RAG
- Weather
Reading List

Contact Us

Raygent Associates
PO Box 3701
Manhattan Beach, CA 90266
Phone 1-(310)-871-1231

rod @rayno.com

Share this:

Email
Print

Name
Email
Message
Send a copy of this email to yourself
If you want to submit this form, do not enter anything in this field

Search

Latest
Popular
Tags

Biotechnology Archives: Human Genome Sciences-Anthrax and Lupus May 20, 2013
Major Sell-Off in Biopharmaceutical Stocks: Caution and Raise Cash -Update 1 May 16, 2013
Emerging Biomarker Companies Redux: BGMD,RGDX,VRML Positioned for Growth May 15, 2013
Bull Market Rolls On And Biotech Sector Hits New All Time Highs May 14, 2013
VRML Soars 40% On Equity Infusion: Biomarker Face-Off Redux with BGMD,RGDX May 9, 2013

Rayno Life Science Tools And Dx Portfolio Update:Immucor Beats 6/20 update April 6, 2011
Rayno Biopharmaceutical Portfolio 2011 Up 1.75% Today March 3, 2011
Reporting from the JPMorgan 29th Annual Healthcare Conference 2011 January 18, 2011
Rayno 2009 Biotechnology Portfolio-Mid Year Update July 13, 2009
Rayno Diagnostics and Tools Portfolio: ILMN, NEOG December 22, 2011

AACC AACC Effect AACR active cellular immunotherapy ADC antibody-drug conjugates Add new tag Alzheimer Disease antibiotics antibody-drug conjugates antisense antiviral ASCO B2-microglobulin BATTLE Trial bearish nat gas market biodiscovery BIO ETF's biogenerics BIOgraph biomarkers biomedical biosimilars Biotech ETF's biotechnology sector biotech portfolios and ETFs biotech stocks C.difficile cancer vaccines immunotherapy clinical diagnostics companion diagnostics diagnostics genomics genomics personalized medicine genzyme GILD HCV healthcare reform Icahn Effect life science ETF's mass spec molecular diagnostics personalized medicine pharmacogenomics targeted therapy venture capital

Reuters Healthcare

UK first in EU to get Merck's new Schmallenberg vaccine
U.S. court ruling favors Cubist in patent case vs Hospira
UPDATE 1-U.S. charges 3 NYU researchers in Chinese bribery case
Regeneron settles all pending litigation with Roche's Genentech

Subscribe to our blog

Enter your email address below to get all of our posts.

Your email:

About the Author

Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.

Raygent Reads

Bloomberg – Business & Financial News, Breaking News Headlines
GEN | Genetic Engineering & Biotechnology News – Biotech from Bench to Business
GenomeWeb
Investor Uprising – The Individual Investor Intelligence Network
Pullan's Pieces for Drug Partnering
ZeroHedge

Copyright © 2009-2012 Raygent.com

Raygent Associates | PO Box 3701 Manhattan Beach, CA 90266 | Phone 1-(310)-871-1231 | rod@rayno.com

Send to Email Address Your Name Your Email Address

Cancel

Post was not sent - check your email addresses!

Email check failed, please try again

Sorry, your blog cannot share posts by email.